⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8922980 | 1.00 | — | — | |
| SCHEMBL204337 | 1.00 | — | — | |
| SCHEMBL25322600 | 0.86 | GABRR1 (0.41) | — | |
| SCHEMBL4338255 | 0.86 | GABRR1 (0.41) | — | |
| SCHEMBL13006588 | 0.81 | — | — | |
| SCHEMBL22315077 | 0.81 | — | — | |
| SCHEMBL29220380 | 0.81 | — | — | |
| SCHEMBL18305943 | 0.80 | — | — | |
| SCHEMBL21930790 | 0.80 | TAS1R3 (0.42) | — | |
| SCHEMBL1494486 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112262129-B | Triazacyclododecanesulfonamide (\"TCD\") based protein secretion inhibitors | 科智生命科学公司 | 2024-05-14 | — | — | CN | disclosed |
| WO-2023154818-A1 | MUCOSAL ADMINISTRATION METHODS AND FORMULATIONS | MODERNATX, INC. (US) | 2023-08-17 | — | — | WO | disclosed |
| EP-3765447-B1 | TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS | KEZAR LIFE SCIENCES (US) | 2023-07-12 | — | — | EP | disclosed |
| WO-2023076598-A1 | LIPID AMINES | MODERNATX, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| US-11578055-B2 | Triazacyclododecansulfonamide (“TCD”)-based protein secretion inhibitors | KEZAR LIFE SCIENCES (US) | 2023-02-14 | — | — | US | disclosed |
| US-20220402891-A1 | TRIAZACYCLODODECANSULFONAMIDE (TCD)-BASED PROTEIN SECRETION INHIBITORS | ENODIA THERAPEUTICS SAS (FR) | 2022-12-22 | — | — | US | disclosed |
| EP-3464287-B1 | ANIMAL AND HUMAN ANTI-MALARIAL AGENTS | CELGENE CORP (US) | 2022-06-08 | — | — | EP | disclosed |
| US-11344554-B2 | Animal and human anti-malarial agents | CELGENE CORPORATION (US) | 2022-05-31 | — | — | US | disclosed |
| US-20210340121-A1 | SUBSTITUTED PYRIDINE AND PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-11-04 | — | — | US | disclosed |
| US-11008302-B2 | Substituted pyridine and pyrimidines and their use as GluN2B receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2021-05-18 | — | — | US | disclosed |
| US-5300523-A | Binding serotonin receptors, treating nervous system disorders | BAYER AKTIENGESELLSCHAFT (DE) | 1994-04-05 | — | — | US | disclosed |
| US-5298513-A | Serotonin antagonist | BAYER AKTIENGESELLSCHAFT (DE) | 1994-03-29 | — | — | US | disclosed |
| EP-0332968-B1 | 1,3,4,5-Tetrahydrobenz[c,d]indoles | BAYER AG (DE) | 1993-06-02 | — | — | EP | disclosed |
| EP-0270947-B1 | SUBSTITUTED BASIC 2-AMINOTETRALINES | BAYER AG (DE) | 1993-05-19 | — | — | EP | disclosed |
| US-5153225-A | For treating disorders of the central nervous system, cardiovascular system and intestinal tract | BAYER AKTIENGESELLSCHAFT (DE) | 1992-10-06 | — | — | US | disclosed |
| US-5137901-A | For binding 5-HT 1 receptors; treating central nervous system disorders | BAYER AKTIENGESELLSCHAFT (DE) | 1992-08-11 | — | — | US | disclosed |
| US-5026857-A | Cetnral nervous system disorders; antiserotonine agent | BAYER AKTIENGESELLSCHAFT (DE) | 1991-06-25 | — | — | US | disclosed |
| US-5021438-A | Having affinity for 5-hydroxytryptamine receptors; treating central nervous system and cardiovascular disorders | BAYER AKTIENGESELLSCHAFT (DE) | 1991-06-04 | — | — | US | disclosed |
| US-4880802-A | CENTRAL NERVOUS SYSTEM | BAYER AKTIENGESELLSCHAFT (DE) | 1989-11-14 | — | — | US | disclosed |
| EP-0270947-A2 | Substituted basic 2-aminotetralines | BAYER AG (DE) | 1988-06-15 | — | — | EP | disclosed |